Form 8-K - Current report:
SEC Accession No. 0001104659-25-002043
Filing Date
2025-01-08
Accepted
2025-01-08 16:25:20
Documents
17
Period of Report
2025-01-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm252622d1_8k.htm   iXBRL 8-K 30408
2 EXHIBIT 1.1 tm252622d1_ex1-1.htm EX-1.1 225846
3 EXHIBIT 5.1 tm252622d1_ex5-1.htm EX-5.1 66277
4 EXHIBIT 99.1 tm252622d1_ex99-1.htm EX-99.1 10859
8 GRAPHIC tm252622d1_ex99-1img001.jpg GRAPHIC 4343
  Complete submission text file 0001104659-25-002043.txt   582124

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA qure-20250107.xsd EX-101.SCH 3012
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE qure-20250107_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qure-20250107_pre.xml EX-101.PRE 22357
19 EXTRACTED XBRL INSTANCE DOCUMENT tm252622d1_8k_htm.xml XML 3600
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 25518835
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)